LRIG1 and central nervous system cancer: LRIG1 is a potent inhibitor of GBM growth in clinically-relevant experimental glioma models, largely independent of EGFR status (Johansson et al., 2013) and is thought to restrict proliferation and aggressiveness of GSCs (Mao et al., 2017).